Does a low omega-3 index indicate inadequate tissue incorporation of omega-3s and reduced SPM production?

The omega-3 index, which measures erythrocyte membrane eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), serves as a stable biomarker of systemic fatty acid status and long-term tissue incorporation.

Tissue incorporation and systemic representation

• Red blood cell (RBC) membrane EPA and DHA levels correlate strongly with major organ tissues. Human biopsy studies demonstrate a high correlation coefficient ($r \approx 0.82$) between RBC membrane concentrations and myocardial levels, while also reflecting skeletal muscle and gastrointestinal tissue composition.
• Because erythrocytes have a 120-day lifespan, a low omega-3 index serves as a stable, chronic marker of systemic deficiency rather than representing temporary, short-term dietary fluctuations in plasma.

Mechanistic pathways of inflammatory resolution

• Cell membrane-bound EPA, DHA, and docosapentaenoic acid (DPA) are the direct precursors for specialized pro-resolving mediators (SPMs), including resolvins, protectins, and maresins. These bioactive lipids are not stored pre-formed; they are enzymatically cleaved and synthesized on-demand during inflammatory events.
• Because SPM production is highly substrate-limited, depleted membrane levels of EPA, DHA, and DPA restrict biosynthetic flux through the lipoxygenase (LOX) and cyclooxygenase (COX) pathways. This substrate deficiency limits the formation of critical intermediate oxylipins (such as 18-HEPE and 17-HDHA), thereby reducing downstream SPM synthesis and compromising the body's capacity to actively resolve inflammation.

Bottom line

• A low omega-3 index directly indicates inadequate tissue incorporation of long-chain omega-3 fatty acids, which impairs the on-demand enzymatic synthesis of specialized pro-resolving mediators and limits the active resolution of systemic inflammation.